Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Kanami Shimura, Norie Murayama, Saki Tanaka, Shunsuke Onozeki & Hiroshi Yamazaki. (2019) Suitable albumin concentrations for enhanced drug oxidation activities mediated by human liver microsomal cytochrome P450 2C9 and other forms predicted with unbound fractions and partition/distribution coefficients of model substrates. Xenobiotica 49:5, pages 557-562.
Read now
Read now
M. Ufer, B. Kammerer, R. Kahlich, J. Kirchheiner, ü. Yasar, J. brockmöller & A. Rane. (2004) Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica 34:9, pages 847-859.
Read now
Read now
Yune-Fang Ueng, Ya-Hui Kuo, Hsiao-Chi Peng, Ta-Liang Chen, Woan-Ching Jan, F. Peter Guengerich & Yun-Lian Lin. (2003) Diterpene quinone tanshinone IIA selectively inhibits mouse and human cytochrome P4501A2. Xenobiotica 33:6, pages 603-613.
Read now
Read now
Slobodan Rendic. (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews 34:1-2, pages 83-448.
Read now
Read now
N. Hagen, A. K. Olsen, J. V. Andersen, J. Tjørnelund & S. H. Hansen. (2002) Characterization of mixtures of recombinant human cytochrome P450s as a screening model for metabolic stability in drug discovery. Xenobiotica 32:9, pages 749-759.
Read now
Read now
C. Emoto, H. Yamazaki, S. Yamasaki, N. Shimada, M. Nakajima & T. Yokoi. (2000) Use of everted sacs of mouse small intestine as enzyme sources for the study of drug oxidation activities in vitro. Xenobiotica 30:10, pages 971-982.
Read now
Read now
H. Yamazaki, M. Suzuki, K. Tane, N. Shimada, M. Nakajima, T. Yokoi. (2000) In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica 30:1, pages 61-70.
Read now
Read now
Articles from other publishers (33)
Chanan Shaul, Simcha Blotnick, Liat Adar, Mordechai Muszkat, Meir Bialer & Yoseph Caraco. (2022) Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance. Clinical Pharmacokinetics 61:8, pages 1187-1198.
Crossref
Crossref
Victoria V. Shumyantseva, Tatiana V. Bulko, Polina I. Koroleva, Evgeniya V. Shikh, Anna A. Makhova, Maryia S. Kisel, Irina V. Haidukevich & Andrei A. Gilep. (2022) Human Cytochrome P450 2C9 and Its Polymorphic Modifications: Electroanalysis, Catalytic Properties, and Approaches to the Regulation of Enzymatic Activity. Processes 10:2, pages 383.
Crossref
Crossref
Paola Panicco, Silvia Castrignanò, Sheila J. Sadeghi, Giovanna Di Nardo & Gianfranco Gilardi. (2021) Engineered human CYP2C9 and its main polymorphic variants for bioelectrochemical measurements of catalytic response. Bioelectrochemistry 138, pages 107729.
Crossref
Crossref
Meiting Jiang, Yangxu Zhou, Jiayu Chen, Wenlong Zhang, Zhidan Sun, Mengnan Qin, Yan Liu & Gaofeng Liu. (2020) Effects of Herba Erigerontis injection on pharmacodynamics and pharmacokinetics of warfarin in rats in vivo. Basic & Clinical Pharmacology & Toxicology 128:3, pages 386-393.
Crossref
Crossref
Tomonori Miura, Shotaro Uehara, Makiko Shimizu, Norie Murayama, Masahiro Utoh, Hiroshi Suemizu & Hiroshi Yamazaki. (2019) Different Roles of Human Cytochrome P450 2C9 and 3A Enzymes in Diclofenac 4′- and 5-Hydroxylations Mediated by Metabolically Inactivated Human Hepatocytes in Previously Transplanted Chimeric Mice. Chemical Research in Toxicology 33:2, pages 634-639.
Crossref
Crossref
Na Gao, Xin Tian, Yan Fang, Jun Zhou, Haifeng Zhang, Qiang Wen, Linjing Jia, Jie Gao, Bao Sun, Jingyao Wei, Yunfei Zhang, Mingzhu Cui & Hailing Qiao. (2016) Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes. European Journal of Pharmaceutical Sciences 92, pages 86-97.
Crossref
Crossref
Addepalli Pavani, Shaik Mohammad Naushad, Rajasekar Manoj Kumar, Murali Srinath, Amaresh Rao Malempati & Vijay Kumar Kutala. (2016) Artificial neural network-based pharmacogenomic algorithm for warfarin dose optimization. Pharmacogenomics 17:2, pages 121-131.
Crossref
Crossref
Hiroshi YAMAZAKI, Eriko KUNIKANE, Sayako NISHIYAMA, Norie MURAYAMA, Makiko SHIMIZU, Yuichi SUGIYAMA, Koji CHIBA & Toshihiko IKEDA. (2015) Human Plasma Concentrations of Tolbutamide and Acetaminophen Extrapolated from <i>in vivo</i> Animal Pharmacokinetics Using <i>in vitro</i> Human Hepatic Clearances and Simple Physiologically Based Pharmacokinetic Modeling for Radio-labeled Microdose Clinical Studies. RADIOISOTOPES 64:8, pages 509-519.
Crossref
Crossref
Yune-Fang Ueng, Chien-Chih Chen, Hiroshi Yamazaki, Kazuma Kiyotani, Yu-Ping Chang, Wei-Shang Lo, Ding-Tzai Li & Pei-Lun Tsai. (2013) Mechanism-based Inhibition of CYP1A1 and CYP3A4 by the Furanocoumarin Chalepensin. Drug Metabolism and Pharmacokinetics 28:3, pages 229-238.
Crossref
Crossref
Junichi Iida, Toshiyuki Kudo, Kento Shimada, Yoshiyuki Yatsuno, Saori Yamagishi, Satoshi Hasegawa, Hideyuki Ike, Toru Sato, Hajime Kagaya & Kiyomi Ito. (2013) Investigation of the Safety of Topical Metronidazole from a Pharmacokinetic Perspective. Biological and Pharmaceutical Bulletin 36:1, pages 89-95.
Crossref
Crossref
Yoshio Hosoi, Yasuhiro Uno, Norie Murayama, Hideki Fujino, Mitsunori Shukuya, Kazuhide Iwasaki, Makiko Shimizu, Masahiro Utoh & Hiroshi Yamazaki. (2012) Monkey liver cytochrome P450 2C19 is involved in R- and S-warfarin 7-hydroxylation. Biochemical Pharmacology 84:12, pages 1691-1695.
Crossref
Crossref
Wei-Sheng Lo, Yun-Ping Lim, Chien-Chih Chen, Chih-Chien Hsu, Pavel Souček, Chul-Ho Yun, Wen Xie & Yune-Fang Ueng. (2012) A dual function of the furanocoumarin chalepensin in inhibiting Cyp2a and inducing Cyp2b in mice: the protein stabilization and receptor-mediated activation. Archives of Toxicology 86:12, pages 1927-1938.
Crossref
Crossref
Y Liu, H Jeong, H Takahashi, K Drozda, S R Patel, N L Shapiro, E A Nutescu & L H Cavallari. (2012) Decreased Warfarin Clearance Associated With the CYP2C9 R150H (*8) Polymorphism. Clinical Pharmacology & Therapeutics 91:4, pages 660-665.
Crossref
Crossref
Yun-Lian Lin, Ming-Jaw Don, Ya-Hui Kuo, Ruei-Ming Chen & Yune-Fang Ueng. (2006)
Induction of cytochrome P450-dependent monooxygenase by extracts of the medicinal herb
Salvia miltiorrhiza
. Journal of Pharmacy and Pharmacology 58:4, pages 521-527.
Crossref
Crossref
Yueh-Ching Chou, Yu-Ting Chung, Tsung-Yun Liu, Szu-Yu Wang, Gar-Yang Chau, Chin-Wen Chi, Pavel Souček, Kristopher W. Krausz, Harry V. Gelboin, Chen-Hsen Lee & Yune-Fang Ueng. (2010) The oxidative metabolism of dimemorfan by human cytochrome P450 enzymes. Journal of Pharmaceutical Sciences 99:2, pages 1063-1077.
Crossref
Crossref
Makiko Kusama, Kazuya Maeda, Koji Chiba, Akinori Aoyama & Yuichi Sugiyama. (2008) Prediction of the Effects of Genetic Polymorphism on the Pharmacokinetics of CYP2C9 Substrates from In Vitro Data. Pharmaceutical Research 26:4, pages 822-835.
Crossref
Crossref
Bent H. Hellum, Zhuohan Hu & Odd Georg Nilsen. (2007) The Induction of CYP1A2, CYP2D6 and CYP3A4 by Six Trade Herbal Products in Cultured Primary Human Hepatocytes. Basic & Clinical Pharmacology & Toxicology 100:1, pages 23-30.
Crossref
Crossref
Yune-Fang Ueng, Chih-Hang Hsieh & Ming-Jaw Don. (2005) Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole. Food and Chemical Toxicology 43:5, pages 707-712.
Crossref
Crossref
F. Peter Guengerich. 2005. Cytochrome P450. Cytochrome P450
377
530
.
Bryan D. Marks, David V. Thompson, Tony A. Goossens & Olga V. Trubetskoy. (2004) High-Throughput Screening Assays for the Assessment of CYP2C9*1, CYP2C9*2, and CYP2C9*3 Metabolism Using Fluorogenic Vivid® Substrates. SLAS Discovery 9:5, pages 439-449.
Crossref
Crossref
Andrea R. Redman, Leslie J. Dickmann, Robert S. Kidd, Joyce A. Goldstein, Denise M. Ritchie & Yuen Yi Hon. (2016) CYP2C9 Genetic Polymorphisms and Warfarin. Clinical and Applied Thrombosis/Hemostasis 10:2, pages 149-154.
Crossref
Crossref
Izumi Iida, Atsunori Miyata, Masayuki Arai, Mitsuyo Hirota, Masayuki Akimoto, Shohei Higuchi, Kaoru Kobayashi & Kan Chiba. (2004) CATALYTIC ROLES OF CYP2C9 AND ITS VARIANTS (CYP2C9*2 AND CYP2C9*3) IN LORNOXICAM 5′-HYDROXYLATION. Drug Metabolism and Disposition 32:1, pages 7-9.
Crossref
Crossref
Yune-Fang Ueng, Ya-Hui Kuo, Shu-Yun Wang, Yun-Lian Lin & Chieh-Fu Chen. (2004) Induction of CYP1A by a diterpene quinone tanshinone IIA isolated from a medicinal herb Salvia miltiorrhiza in C57BL/6J but not in DBA/2J mice. Life Sciences 74:7, pages 885-896.
Crossref
Crossref
Yune-Fang Ueng, Woan-Ching Jan, Lie-Chwen Lin, Ta-Liang Chen, F. Peter Guengerich & Chieh-Fu Chen. (2002) The Alkaloid Rutaecarpine Is a Selective Inhibitor of Cytochrome P450 1A in Mouse and Human Liver Microsomes. Drug Metabolism and Disposition 30:3, pages 349-353.
Crossref
Crossref
Jooran S. Kim, Anne N. Nafziger, Andrea Gaedigk, Leslie J. Dickmann, Allan E. Rettie & Joseph S. BertinoJr.Jr.. (2013) Effects of Oral Vitamin K on S‐ and R‐Warfarin Pharmacokinetics and Pharmacodynamics: Enhanced Safety of Warfarin as a CYP2C9 Probe. The Journal of Clinical Pharmacology 41:7, pages 715-722.
Crossref
Crossref
Hong-Guang XieRichard B KimAlastair JJ WoodC Michael Stein. (2001) Molecular Basis of Ethnic Differences in Drug Disposition and Response. Annual Review of Pharmacology and Toxicology 41:1, pages 815-850.
Crossref
Crossref
Cuyue Tang, Magang Shou, Thomas H. Rushmore, Qin Mei, Punam Sandhu, Eric J. Woolf, Mark J. Rose, Alyssa Gelmann, Howard E. Greenberg, Inge De Lepeleire, Anne Van Hecken, Paul J. De Schepper, David L. Ebel, Jules I. Schwartz & A. David Rodrigues. (2001) In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 11:3, pages 223-235.
Crossref
Crossref
Andrea R. Redman. (2012) Implications of Cytochrome P450 2C9 Polymorphism on Warfarin Metabolism and Dosing. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 21:2, pages 235-242.
Crossref
Crossref
Mary H.H. Ensom, Thomas K.H. Chang & Payal Patel. (2001) Pharmacogenetics. Clinical Pharmacokinetics 40:11, pages 783-802.
Crossref
Crossref
Vilia Ann Payne, Yan-Tyng Chang & Gilda H. Loew. (1999) Homology modeling and substrate binding study of human CYP2C9 enzyme. Proteins: Structure, Function, and Genetics 37:2, pages 176-190.
Crossref
Crossref
Sükrü Aynacioglu, Jürgen Brockmöller, Steffen Bauer, Christoph Sachse, Pinar Güzelbey, Zuhal Öngen, Muradiye Nacak & Ivar Roots. (2001) Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. British Journal of Clinical Pharmacology 48:3, pages 409-415.
Crossref
Crossref
Ümit Yasar, Erik Eliasson, Marja-Liisa Dahl, Inger Johansson, Magnus Ingelman-Sundberg & Folke Sjöqvist. (1999) Validation of Methods for CYP2C9 Genotyping: Frequencies of Mutant Alleles in a Swedish Population. Biochemical and Biophysical Research Communications 254:3, pages 628-631.
Crossref
Crossref
Victoria. Shumyantseva, Tatiana Bulko, Polina Koroleva, Evgeniya Shich, Anna Makhova, Maria Kisel, Irina Haidukevich & Andrei Gilep. (2021) Human Cytochrome P450 2C9 and its Polymorphic Modifications: Electroanalysis, Catalytic Properties and Approaches to the Regulation of Enzymatic Activity. SSRN Electronic Journal.
Crossref
Crossref